DrugCendR Inc. Announces the Appointment of Dr. Daniel Von Hoff as Clinical Advisor

LA JOLLA, Calif., Aug. 20, 2019 (GLOBE NEWSWIRE) — DrugCendR, Inc., a clinical-stage biotech company developing next generation therapies for the treatment of solid tumors, today announced that Dr. Daniel Von Hoff will be a clinical advisor to the company. In this role, Dr. Von Hoff will guide the company with its clinical development programs.